SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: software salesperson who wrote (9521)1/31/2003 2:25:43 AM
From: Miljenko Zuanic   of 9719
 
Sales,

That Velcade work in hematological cancers is almost clear, at least to me. In several indications it will make nice market penetration, imo.

Early PIb result indicate that it is additive to other cytotoxic agent and may work for selected solid tumors. Regards the hypoxic tumor I early on MLNM tread indicate that this preclinical results needs to be confirmed with surrogate markers in clinic.

I will further speculate that their push for early MM NDA is not to beets Thalidomide or Revimid. Because of the different action mode it can be administrated in combination, but it will be up to CELG to investigate this. Early on market means that they will have (from off-label usage) input from oncologist about other indications worth to explore further. So, clinical decision will not be based on few responders from 50-100 of the selected pts. Something that CELG explored with thalidomide.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News